Online Journal
Front Page 
 
 Donate
 
 Submissions
 
 Announcements
 
 NewsLinks
 
 Special Reports
 
 News Media
 
 Elections & Voting
 
 Health
 
 Religion
 
 Social Security
 
 Analysis
 
 Commentary
 
 Editors' Blog
 
 Reclaiming America
 
 The Splendid Failure of Occupation
 
 The Lighter Side
 
 Reviews
 
 The Mailbag
 
 Online Journal Stores
 Official Merchandise
 Amazon.com
 
 Links
 
 Join Mailing List
Search

Health Last Updated: Feb 27th, 2008 - 00:47:20


Despite 5,000 lawsuits, Wyeth and US endocrinologist group hope for HRT comeback
By Martha Rosenberg
Online Journal Contributing Writer


Feb 27, 2008, 00:47

Email this article
 Printer friendly page

A reduction in a jury award for a drug that caused cancer from $134 million to $58 million would not normally be cause to rejoice. But it has not been a normal year for hormone maker Wyeth.

The Madison, NJ-based drug company faces 5,300 Prempro and Premarin related law suits in addition to the one it just lost -- but with damages reduced -- in Reno, Nev., brought by three women with breast cancer.

Wyeth had asked Washoe District Judge Robert Perry for a mistrial.

Selling a product that's proven to cause cancer isn't easy for Wyeth.

In January, it announced it was selling the one million square-foot Rouses Point, NY, plant, where it made its horse-urine derived drugs and employed 900, and was cutting a full 10 percent of its work force.

Nor is the Food and Drug Administration (FDA) rubber-stamping new drugs from the company which made fenfluramine/phentermine and some say has a "safety second" culture.

Last year it rejected Wyeth's osteoporosis drug, bazedoxifene, because of stroke and blood clot problems; schizophrenia drug, bifeprunox, because it was not as effective as other drugs on the market and menopause drug, Pristiq, because of serious heart or liver complications experienced by trial participants.

The FDA is "establishing monopolies" by rejecting drugs just because they're inferior to existing ones, growled outgoing Wyeth CEO Bob Essner when bifeprunox was not approved. After all, the public liked Vioxx and Vytorin just fine and they weren't better than their predecessors, he might have been thinking.

No wonder Wyeth lawyers have been browbeating the FDA, successfully it turns out, to regulate pharmacy compounded bioidentical hormones that have unseated its products in many women's medicine chests.

Wyeth is not alone in hoping for an HRT comeback.

Since HRT was found by the Women's Health Initiative in 2002 to cause a 26 percent increased risk of breast cancer, 29 percent increased risk of heart attack, 41 percent increased risk of stroke and 100 percent increased risk of blood clots, a study in the January issue of Cancer Epidemiology, Biomarkers and Prevention found the cancers also move quickly.

Women who took combined estrogen/progestin hormone-replacement therapy for just three years had four times the usual risk of lobular breast cancer, which accounts for about 10 percent of invasive breast cancer.

The effect of millions of HRT users saying, "You want us to take WHAT?" after the WHI study -- 75 percent quit -- was also dramatic. There was an 8.6 percent reduction in overall breast cancer between 2001 and 2004 and 14.7 percent reduction for estrogen-receptor positive breast cancer.

But "studies" by doctors who don't want to give up the HRT gravy train appear with increasing regularity, promoting results that seek to reverse or spin the WHI findings.

HRT actually protects against heart disease and reduces calcification of the arteries -- two original, disproved HRT selling points -- say the authors of the new crop of "timing hypothesis/therapeutic window of opportunity" analyses, hoping the memory of the American public is as short as their practice's funds without trumped up HRT profits.

Researchers even resuscitated the discredited claim that HRT protects against dementia at a meeting of the American Academy of Neurology last year. And there are rumblings that HRT's ability to lower colon cancer could be of value. (Viz: HRT causes breast cancer, heart attack, stroke and blood clots but you might not get colon cancer!)

Of course some doctors have noted the creeping HRT revisionism.

Enthusiasm for the Yes But studies "far exceeds the science" and does not "alter current recommendations that hormone therapy should never be used to prevent heart disease," says Dr. Helen Roberts, senior lecturer in women's health at Auckland University. For one thing, "the risk of stroke was elevated regardless of how many years had elapsed since menopause," she says of the new studies.

But others like the American Association of Clinical Endocrinologists (AACE) have jumped on the HRT bandwagon.

"This is an important and meaningful analysis for women who can benefit from Hormone Replacement Therapy," said Richard Hellman, AACE President, about a study which indicated HRT did not elevate cardiovascular disease risk in some women.

And a position paper on the AACE site says, "Given the powerful effects of estrogen therapy in relieving menopausal symptoms, we believe that physicians may safely counsel women to use estrogen for the relief of menopausal symptoms."

Some suggest Wyeth money is behind the AACE position.

After all, Hellman also came out for controversial diabetes drug Avandia when the FDA questioned the drug's safety. "There is still not a good scientific basis for assessing the drug's safety in all patients. But, we can say, if there is an increased risk for a heart attack, it appears to be a relatively small risk," he wrote on the AACE site.

And even though he added the organization has "no financial ties to the company, GlaxoSmithKline, that manufactures Avandia," AACE's annual report for 2006-2007 thanks GlaxoSmithKline four times for its financial support.

Wyeth money could help for future court cases.

Martha Rosenberg is a Staff Cartoonist at the Evanston Roundtable. Her work has appeared in the Chicago Tribune, LA Times, San Francisco Chronicle, Boston Globe, Providence Journal. Arizona Republic, New Orleans Times-Picayune and other newspapers. She can be reached at: mrosenberg@evmark.org.

Copyright © 1998-2007 Online Journal
Email Online Journal Editor

Top of Page

Health
Latest Headlines
Pandemic response plan: let the elderly, the sick, and the poor die
How to get universal health care
Despite 5,000 lawsuits, Wyeth and US endocrinologist group hope for HRT comeback
Time to end profit-driven mandatory vaccination racket
For-profit health care: More than one way to scan a CAT
Accused of hiding drug dangers again, Big Pharma starts 2008 defending itself
Medical researchers patented AIDS cure in 1990
The polio vaccine, AIDS, and their US-made viruses
Inside Bush's FDA: A perpetual leaker of insider information and the slipshod testing of generic drugs
So . . . what's this here single-payer health care thing all about anyway?
AIDS estimates surge in America
Teenage girl dies so CIGNA execs can get richer
Drugs not hugs, say pharma linked child psychiatrists
Medicare Part D destroys the lives of senior citizens, the poor, and the sick
Eli Lilly's latest curse: Cymbalta
FDA, industry insiders derail approval of new cancer treatments
The topic of cancer
Why Bush should have signed the children�s health act
S-CHIP veto: The millstone around Bush's neck
Canada unveils mental health board: Prime Minister Harper�s cure worse than disease